Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January–June 2019

Major investment in production facilities secures quality and capacity for the futureQ2 2019 · Net sales for the period amounted to SEK 12.5 (2.5) million and earnings to SEK -18.3 (-16.7) million, which corresponds to earnings per share of SEK -0.11 (-0.40).   · Gross profit amounted to SEK -1.4 million, which is an improvement of SEK 4.3 million compared to the corresponding period in 2018 and SEK 1.2 million compared to Q1 2019.  · Cash and cash equivalents as at June 30 amounted to SEK 14.9 (29.2) million.  · An investment decision was made to acquire sputtering machines

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

Several advances in the clinical portfolioApril – JuneSignificant events during the quarter · Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The analysis shows an early indication that MIV-818 works as expected, i.e. the substance has the intended liver-directed effect. · New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO. · Positive data from the investigator-initiated study evaluating the efficacy of remetinostat in basal cell carcinoma (BCC) patients presented at the SID annual meeting. · New

Episurf Medical takes the next step in partnership regarding its AI-based imaging technology

Episurf Medical (NASDAQ: EPIS B), a pioneer and leader in individualised technologies for painful joint injuries, today announces that it has entered into an agreement with a US-based orthopaedic company. This company will have exclusive rights to use Episurf Medical’s AI-based medical imaging technology for allograft products in North America and the UK. This agreement follows a Letter of Intent, in which the two companies announced that they had entered into in July 2019. The agreement covers an initial evaluation period during which the potential use of Episurf Medical’s proprietary AI-

EAB Group Plc continues measures to increase profitability and starts planning a new efficiency program

EAB Group Plc, Inside Information, Stock Exchange Release, 28 August 2019, 9:30 a.m. (EET) EAB Group Plc continues measures to increase profitability and starts planning a new efficiency program EAB Group Plc (EAB, Company) continues measures to increase profitability and starts planning a new efficiency program. The planned efficiency program has a goal of achieving savings of 1 million euros in personnel and other costs. EAB has during the last years invested into internal efficiency in the form of new it-systems and new ways to organise work. Starting from the summer 2019 the

EAB Group Plc will commence acquiring the company’s own shares

EAB Group Plc, Stock Exchange Release, 28 August 2019, 9.30 a.m. (EET) EAB Group Plc will commence acquiring the company’s own shares The Board of Directors of EAB Group Plc has decided in its meeting on 28 August 2019 to commence acquiring the company’s own shares on the basis of the authorization given by EAB Group Plc´s Annual General Meeting held on 5 April 2019. The Board of Directors has decided that the maximum number of shares to be acquired is 75,000, corresponding to approximately 0.5% of the total number of shares, up to a maximum of 200,000 euro. The shares shall be

Camanio Care publishes interim report January-June 2019

The complete interim report is available as a PDF on the company website www.camanio.com. It is also attached to this press release.Summary Figures in parentheses refer to the corresponding period during the previous year, unless otherwise is stated.  1 APRIL – 30 JUNE 2019 1       Total revenue for the period amounted to kSEK 1,929 (kSEK 2,739)                 2     Net sales for the period amounted to kSEK 1,721 (kSEK 1,204) 3     Operating profit/loss was kSEK -5,505 (kSEK -4,562) 4     Profit/loss after financial items was kSEK -5,977 (kSEK -4,762) 5     Earnings

Fasenra granted US Orphan Drug Designation for

28 August 2019 07:05 BST Fasenra granted US Orphan Drug Designationfor eosinophilic oesophagitis AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted  Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a rare, chronic, inflammatory disease that occurs when eosinophils, a type of white blood cell, accumulate in the oesophagus causing injury and inflammation.1 The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of

Recruitment begun for new President of Hemköp

Hemköp’s President, Thomas Gäreskog, will be leaving his current role once his successor has taken office.After seven years in the role as President of Hemköpskedjan AB, Thomas Gäreskog will be leaving his assignment. Thomas will continue to serve as President of Hemköp until his successor has been recruited and taken office. Thomas will thereafter work with specific business development projects within the Axfood Group. “I will continue the work on strengthening Hemköp’s offering and concept in line with existing plans until my successor is in place, and I look forward thereafter to

Interim report April - June 2019.

The full Interim report is available on Brighter's website https://brighter.se. The Interim report is also attached as a pdf file to this press release. April - June 2019. ·  Capitalized expenditure for development work reached SEK 9,869 thousand (5,183)   ·  Operating result amounted to SEK -19,467 thousand (-14,278) ·  Result before tax amounted to SEK -23,671 thousand (-15,496). ·  Earnings per share, before dilution amounted to SEK -0.29 (-0.25). ·  Earnings per share after dilution SEK -0.29 (SEK -0.25). January - June 2019. · Capitalized expenditure for

Clavister Q2 2019: 28% growth, 42% improved gross profit

August 28, 2019. Örnsköldsvik, Sweden. Clavister, a leader in high-performance cybersecurity solutions, released its latest quarterly report today. “The second quarter started with a very positive recognition: in a market report for 2018, independent industry analyst Gartner recognized Clavister as the fastest-growing supplier of security products within the Unified Threat Management segment. Not only is this an honorable appreciation, but more so a very positive acknowledgement of our growth strategy. Our focus on growth and improved margins has paid off during the quarter, with a

Interim report for the period January 1 - June 30, 2019

Net sales increased during the quarter to SEK 23.9 million (12.2), attributable to deliveries within the prioritized customer segments geothermal and maritime. Climeon has expanded globally through the establishment of a subsidiary in Japan. The company sees an increase of interest in Maritime and received an additional order from Fincantieri/Virgin Voyages during the quarter. Operating profit amounted to SEK -33.9 million (-25.8) and profit after financial items amounted to SEK -34.9 million (-25.9). The order backlog totaled SEK 800.8 million (739.7) at the end of the quarter.SECOND

EAB Group Plc’s half-year report for January–June 2019 – Group’s IFRS turnover and comparable net turnover decreased by 4% and the loss for the period amounted to EUR 0.8 million

EAB Group Plc, Stock Exchange Release, 28 August 2019, 9:00 a.m. (EET) EAB Group Plc’s half-year report for January–June 2019 – Group’s IFRS turnover and comparable net turnover decreased by 4% and the loss for the period amounted to EUR 0.8 million EAB Group's (hereinafter EAB or Group) IFRS net turnover during the period 1 January–30 June 2019 amounted to EUR 9.3 million (EUR 9.8 million in H1/2018) and profit for the period to -EUR 0.8 million (EUR 1.2 million in H1/2018). The Group's operating profit was -EUR 0.8 million (EUR 1.4 million in H1/2018). Turnover comprised fee income

Breztri Aerosphere Phase III ETHOS trial met

This announcement contains inside information 28 August 2019 07:00 BST   Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First time the benefit of two doses of a fixed triple-combination therapy has been established in a Phase III chronic obstructive pulmonary disease trial AstraZeneca today announced positive

NENT Group orders ‘Food & Fire’ as next original documentary series

· Six-part documentary created by star Swedish chef Niklas Ekstedt · ‘Food & Fire’ to premiere exclusively on Viaplay in autumn 2019 · NENT Group to premiere at least 20 original productions every year The next original series from Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, will be food documentary ‘Food & Fire’. The six-part series is a follow-up to NENT Group’s critically acclaimed ‘Four Hands Menu’ and will premiere exclusively on NENT Group’s Viaplay streaming service across the Nordic region in autumn 2019. Fire, food and

I-Tech AB (publ) Interim report Q2 2019

Mölndal, August 28, 2019 - I-Tech AB (publ) (ticker ITECH) publish the interim report for the second quarter 2019Summary of the period - Q2 2019 ”Highest sales so far in a single quarter” Net sales for the period amounted to kSEK 12 582 (9 270), which corresponds to an increase in sales of 36% (86%). Operating result amounted to kSEK -906 (-2 544). Net sales for the first half of the year amounted to kSEK 18 752 (13 083), corresponding to an increase in sales of 43% (155%). Operating result amounted to kSEK -5 341 (-5 844). April to June 2019 · The Swedbank Robur Teknik and

Saab appoints Chief Marketing Officer

Saab has appointed Dean Rosenfield as Chief Marketing Officer, responsible for Marketing and Sales. Dean Rosenfield also becomes a member of Group Management.Dean Rosenfield is today head of Market Area Asia Pacific and will take up his new position from 1 January 2020. Dean Rosenfield was earlier the Managing Director for Saab in Australia and has prior to that served in the Australian Army. He will be based in Stockholm. For further information, please contact: Saab Press Centre +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube

NCC to build 129 rental apartments in Älvsjö

In partnership with Familjebostäder, NCC will construct 129 rental apartments close to the new Älvsjöstaden city district, south of Stockholm. The order value is approximately SEK 300 million.Älvsjöstaden is a major urban development area in Älvsjö, comprising a total of approximately 1,500 housing units in three phases. Disused industrial land is to be transformed into a city block in close proximity to commuter trains. “We are pleased that our cooperation with Familjebostäder is growing and that we have had the possibility to work together from an early stage to secure a

Read original

Sivers IMA wins SEK7.3m follow-up order from Fortune 100 customer

Sivers IMA Holding AB (Nasdaq First North: SIVE) today announced that its subsidiary, CST Global, received a new order worth SEK7.3m from an existing, US-based Fortune 100 customer.The order is in addition to existing framework orders CST Global has had with the same company.Sivers IMA Holding AB (Nasdaq First North: SIVE) today announced that its subsidiary, CST Global, received a new order worth SEK7.3m from an existing, US-based Fortune 100 customer.The order is in addition to existing framework orders CST Global has had with the same company.  The new contract is for the supply of

INTERIM REPORT Q2 2019

SummaryFinancial overview April 1 – June 30, 2019  · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 171.9 M (loss: 144.6) · Loss per share, before and after dilution, was SEK 3.52 (loss: 3.30) · On June 30 cash and cash equivalents amounted to SEK 626.8 M (568.2) Significant events during the period April 1 – June 30, 2019  · In April, melflufen was granted additional patent protection in the US until 2033 · In April it was announced that the last patient in the OCEAN trial is estimated to be enrolled during Q1 2020 · In May it was announced

Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited)

Herantis Pharma Plc Company release August 28, 2019 at 9:00am Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited) · Randomized clinical studies in Parkinson’s and lymphedema proceed as planned · Pipeline expansion with next generation xCDNF Highlights January-June 2019 · In March, Herantis Pharma Plc (“Herantis” or “Company”) issued 1,111,982 new shares for the subscription price of €5.20 per share in a directed issue, as authorized by the Extraordinary General Meeting. · In March, Herantis announced that its randomized

Systemair receives major order for Cruise Ships

Press Release, August 28, 2019 Systemair ABs (NASDAQ OMX Stockholm: SYSR) company in the Netherlands has received an order of air handling units, of a value of approx. EUR 3.3 million, from MAC Hamburg for three new ships. The new cruise ships will be built at Meyer Yard in Papenburg Germany. Systemair will deliver 150 air handling units per ship in phases from 2020 till 2022. The units will be placed both in public and technical areas of the ship.  "We are proud to be selected to deliver the units for these prestigious ships. Our factory in the Netherlands has more than 20 years’

First patient included in menstrual migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020.“Standard prophylactic treatments have no efficacy in menstrual migraine. Sepranolone is the most highly targeted prophylactic treatment for menstrual migraine I’ve seen. The protocol for the study is extremely clear and the science highly promising. With 50 million women worldwide living with menstrual migraine the demand for this kind of

The path to 510(k) submission defined after FDA feedback

Biovica has completed the supplement II process which includes written feedback and physical meetings with the FDA in order to define the process for clinical validation for 510(k) submission for DiviTum®. Biovica also announces that an agreement with a leading oncology group has been signed. The agreement enables Biovica to analyze samples from a large, high impact, clinical trial within metastatic breast cancer. Biovica will use the results in the 510(k) FDA submission and has chosen to extend the time plan in order to include the results as an essential part of the submission.Based on

There are no items matching the current filter
There are no more items matching the current filter
Back to top